Xofigo (Radium-223) commonly causes gastrointestinal distress, bone marrow suppression, and peripheral edema during the 6-cycle course. As a targeted radionuclide therapy, it mimics calcium to treat bone metastases, frequently leading to nausea, diarrhea, and significant drops in blood cell counts.
- Hematologic effects: Bone marrow suppression causes anemia, leukopenia, and thrombocytopenia requiring weekly monitoring.
- Gastrointestinal issues: Nausea and severe diarrhea often appear 1–2 weeks after the first injection.
- Skeletal pain: Patients may experience a temporary bone pain flare before achieving symptomatic relief.
- Peripheral edema: Notable swelling frequently occurs in the lower limbs, hands, or arms.
Bookimed Expert Insight: Data from major centers like Memorial Şişli Hospital suggests marrow suppression is the primary cause for treatment pauses. Dr. Cuneyt Turkmen, with over 900 nuclear medicine cases, emphasizes that hemoglobin levels often dip significantly by the third cycle. Patients should prepare for potential treatment delays or blood transfusions midway through the standard 6-month regimen.
Patient Consensus: Many find side effects become more manageable after the second cycle is completed. Aggressive hydration is vital as post-injection diarrhea can feel as intense as severe food poisoning.
